Funicular Funds, LP
Funicular Funds, LP's purchase track record
Funicular Funds, LP has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/20/2023 | LITS | $845K | +27.1% | -26.3% | +18.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
HC Wainwright Reiterates $120 Target on Oruka. HC Wainwright maintained its buy rating on Oruka Therapeutics, keeping its price target at $120. The firm continues to see the company favorably despite recent trading levels well below that target. The analyst consensus average for the stock stands at $153.75, with estimates ranging from $102 to $200.
Transaction History
| LITS | ▼ Sell | Other | 120,600 | $844K | 10/20/2023 | View on chart |
| LITS | ▼ Sell | Other | 30,000 | $210K | 10/11/2023 | View on chart |
| LITS | ▲ Buy | Open Market | 32,040 | $220K | 9/22/2023 | View on chart |
| LITS | ▲ Buy | Open Market | 22,400 | $145K | 9/21/2023 | View on chart |
| LITS | ▲ Buy | Open Market | 80,000 | $481K | 9/20/2023 | View on chart |
| ORKA | ▼ Sell | Other | 1,420,000 | $3.5M | 12/16/2022 | View on chart |
| ORKA | ▼ Sell | Other | 2,580,452 | $0 | 7/1/2022 | View on chart |
| ORKA | ▼ Sell | Other | 2,580,452 | $0 | 7/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Lite Strategy Reports Q4 EPS Improvement and Files Prospectus
Lite Strategy reported fourth-quarter earnings per share of $(0.38), an improvement from $(0.40) in the same period last year. The company also filed a prospectus for an offering of 1.889 million common shares on behalf of selling shareholders. These updates provide context for the stock's current trading range between $0.69 and $2.97.
Lite Strategy Reports Q4 EPS Improvement and Files Prospectus. Lite Strategy reported fourth-quarter earnings per share of $(0.38), an improvement from $(0.40) in the same period last year. The company also filed a prospectus for an offering of 1.889 million common shares on behalf of selling shareholders. These updates provide context for the stock's current trading range between $0.69 and $2.97.